## IONS: Ionis Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 8.0% in mid entry zone (4.0-10.0%), top 3% cross-sectional ranking. Short-term MRS_5 (0.2%) confirms momentum alignment. Outperforming sector by 6.6%. Caution: declining volume (58% of avg).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($76.37)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | B of A Securiti | $97 | $86 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($8.92M) |
| Sells | 21 ($5.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- FMR, LLC: 14.6% (+0.2%)
- Vanguard Group Inc: 10.2% (-1.4%)
- T. Rowe Price Invest: 8.1% (-18.0%)
- Capital World Invest: 7.8% (+1.5%)
- Blackrock Inc.: 6.5% (-4.1%)

### Key Risks

1. Insider selling cluster: $5.9M in recent transactions.
2. Valuation stretched: PEG 25.7x requires aggressive growth execution.
3. Elevated short interest (11.6%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 25.70 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.8x). Analyst sentiment positive (1 raises, avg +13%). Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $12.7B |
| Beta | 0.30 |
| 52W Range | $23.95 - $83.61 |
| Short Interest | 11.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 25.70 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 stable at 8.0% (minimal 5-day change). Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 97th percentile. MRS_5 at 0.2% confirms short-term momentum alignment. AM_20 at 9.1% shows strong absolute momentum above own 20MA. Outperforming sector by 6.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.83), confirming momentum. Volume at 58% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.96% (CS: 97) | Strong |
| RSI_14 | 69.6 | Neutral |
| MACD Histogram | 0.83 | Bullish |
| vs SMA20 | 1.091x | Above |
| vs SMA50 | 1.143x | Above |
| vs SMA200 | 1.763x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $81.99
- **Stop Loss:** $76.37 (6.9% risk)
- **Target:** $90.42 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 133
- **Position Value:** $10,904.67
- **Portfolio %:** 10.90%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-18 (Est: $-1.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.05 | $-0.61 | +41.8% |
| 2025Q2 | $0.16 | $0.85 | +415.1% |
| 2025Q1 | $-1.03 | $-0.92 | +10.4% |
| 2024Q4 | $-0.84 | $-0.43 | +49.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*